Crellastatin A, a PARP-1 Inhibitor Discovered by Complementary Proteomic Approaches

ChemMedChem. 2020 Feb 5;15(3):317-323. doi: 10.1002/cmdc.201900634. Epub 2020 Jan 8.

Abstract

Crellastatin A, a cytotoxic sulfated bis-steroid isolated from the Vanuatu Island marine sponge Crella sp., was selected as an interesting probe for a comprehensive proteomic analysis directed at the characterization of its protein interactors. Given its peculiar structural features, A was submitted to a mass spectrometry-based drug affinity responsive target stability (DARTS) assay combined with (targeted-limited proteolysis-multiple reaction monitoring (t-LiP MRM), rather than a classical affinity purification strategy. Poly-ADP-ribose-polymerase-1 (PARP-1) emerged as the main crellastatin A cellular partner. This result was confirmed by both biochemical and in silico analyses. Further in vitro biological assays highlighted an interesting crellastatin A inhibitory activity on PARP-1.

Keywords: functional proteomics; mass spectrometry.; molecular docking; natural products; target discovery.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dose-Response Relationship, Drug
  • Humans
  • Molecular Structure
  • Norsteroids / chemistry
  • Norsteroids / pharmacology*
  • Poly (ADP-Ribose) Polymerase-1 / antagonists & inhibitors*
  • Poly (ADP-Ribose) Polymerase-1 / metabolism
  • Poly(ADP-ribose) Polymerase Inhibitors / chemistry
  • Poly(ADP-ribose) Polymerase Inhibitors / pharmacology*
  • Proteomics*
  • Structure-Activity Relationship

Substances

  • Norsteroids
  • Poly(ADP-ribose) Polymerase Inhibitors
  • crellasterone
  • PARP1 protein, human
  • Poly (ADP-Ribose) Polymerase-1